VOYAGER THERAPEUTICS INC (VYGR)
Health Care · Gene therapy · NASDAQ
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while advancing early-stage clinical programs.
What VOYAGER THERAPEUTICS INC does
Voyager Therapeutics is a clinical-stage gene therapy company developing AAV gene therapies, non-viral therapeutics, and other biological modalities for neurological and other diseases. The company's pipeline is early-stage, with VY7523 (an anti-tau antibody candidate) in clinical trials and other candidates in preclinical development. The company is substantially dependent on collaborations and licensing agreements with partners including Neurocrine, Novartis, and Alexion for revenue.
Themes: ["gene therapy / CNS","neurological diseases","AAV platform","partnership-driven revenue"]
Fundamentals
- Price$3.68 as of 2026-07-09 close
- Market cap$229M as of 2026-07-10
- 1-year return+6.1% as of 2026-07-09 close
- Net margin-319.6% as of 2026-07-10
- ROE-56.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-45.5% as of 2026-07-10
- Revenue CAGR (3y)-0.4% SEC XBRL
- Beta1.30 as of 2026-07-10
Key risks (from latest filing)
["History of significant losses with no clear path to profitability; early-stage pipeline with regulatory uncertainty and potential for manufacturing complexity in viral vector production","Substantial reliance on collaborations with Neurocrine, Novartis, and Alexion for revenue; termination of any major partnership could materially harm business","Gene therapy safety concerns and regulatory scrutiny following adverse events at other companies; novel vector approach carries unforeseen adverse event risk"]
Competitors & peers
- Gensight Biologics
- Applied Genetic Technologies Corporation (AGTC)
- Regenxbio (RGNX)
- Spark Therapeutics (SPARK)
- Editas Medicine (EDIT)
- Neurocrine Biosciences (NBIX)
- Novartis (NVS)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.